Evidence map›Paper›PMID 31191299›Full record

ArticleFrontiers in pharmacology2019

The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX

Pascale A Cohen, Olivier Loudig, Christina Liu, Joseph Albanese, Susan Fineberg

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Pascale A CohenUniv Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Olivier LoudigCenter for Discovery and Innovation, Hackensack University Medical Center (HUMC), Nutley, NJ, United States.
Christina LiuCenter for Discovery and Innovation, Hackensack University Medical Center (HUMC), Nutley, NJ, United States.
Joseph AlbaneseDepartment of Pathology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY, United States.
Susan FinebergDepartment of Pathology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY, United States.
Albert Einstein College of Medicine · USCenter for Discovery · USMontefiore Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We assessed mRNA and protein expression levels of the ZN217 oncogene in 17 clinical FFPE ER-positive invasive breast cancer specimens with known (low or high) Oncotype DX

Indexed as

biomarkerbreast cancerestrogen-receptor positiveexpressionOncotype DX®ZNF217

Identifiers

PMID31191299
PMCPMC6546897
OpenAlexW2947427621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.